Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

CRISPR Therapeutics AG. (11/28/17). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
  Today Piper Sandler Companies (NYSE: PIPR)
  Group Piper Sandler (Group)
Products Product Barclays Gene Editing & Gene Therapy Summit 2017 New York
  Product 2 Evercore ISI BioPharma Catalyst / Deep Dive Conference 2017 Boston
Index terms Index term CRISPR Therapeutics–Piper Jaffray: investor conference, 201711 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2017
  Index term 2 CRISPR Therapeutics–Citigroup: investor conference, 201712 supply service 1-on-1 meetings at Citi Global Healthcare Conference NY
Persons Person Paganelli, Jennifer (W2O Group 201703)
  Person 2 Brinzey, Christopher F. (Chris) (Westwicke Partners 201703)

CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present or host one-on-one meetings at five upcoming Investor Conferences.

29th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 29, 2017
Fireside Chat: 1:00-1:25 PM ET

Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 30, 2017
Presentation: 3:00-3:20 PM ET
Panel Discussion: 3:40-4:40 PM ET Gene Editing: Putting Molecular Scissors in Real Life Use

Evercore ISI BioPharma Catalyst/Deep Dive Conference
Date: Thursday, November 30, 2017
Fireside Chat: 10:15-10:35 AM ET

Citi 2017 Global Healthcare Conference
Date: Wednesday December 6, 2017
One-on-one meetings only

Guggenheim 4th Annual Boston Healthcare Conference
Date: Tuesday December 13, 2017
One-on-one meetings only

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit

Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290

Chris Erdman
+1 617.307.7227

Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843

Record changed: 2017-12-11


Picture [iito] Plain Stupid Simple 650x80px

More documents for CRISPR Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top